Disclosure under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory Ltd has submitted a routine compliance disclosure under SEBI's Regulation 74(5) for the quarter ended September 30, 2025. The company's Registrar and Transfer Agent, Bigshare Services Pvt. Ltd., confirmed that the regulation does not apply to the company because 100% of its shares are held in demat form. Additionally, no shareholders requested rematerialisation (converting electronic shares back to physical certificates) during the quarter. The filing was signed by Chairman and Managing Director Jagdish Umakant Nayak. The company trades on BSE under scrip code 544220.
This is a standard procedural compliance filing with no material impact on the stock or shareholders. It simply confirms that all shares are fully dematerialised and there were no physical share-related requests, which is normal for a listed company.